Business Standard

Thursday, January 09, 2025 | 07:37 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pfizer vaccine stops 70% Omicron hospitalisations in South Africa: Study

The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov 15-Dec 7

Pfizer Vaccine, Coronavirus vaccine
Premium

Photo: Shutterstock

Reuters JOHANNESBURG
 Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.

The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron.

The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about

Disclaimer: No Business Standard Journalist was involved in creation of this content

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in